All In Biotech

Drug Trial Radar · NCT06099067

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Harmonizing RCT-Duplicate Emulations: A Real World Replication Program Analyzing Three Clinical Trials, CANVAS, LEADER, and SAVOR TIMI in Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Aug 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

239,990

Actual

Start

May 15, 2020

Primary completion

Aug 31, 2023

Study completion Aug 31, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 25, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Replication of three clinical trial emulations CANVAS, LEADER, and SAVOR TIMI that form part of the RCT-Duplicate initiative, sponsored by the FDA and delivered by the Brigham and Women's Hospital and Harvard Medical School. AstraZeneca will use the Instant Health Data platform PANALGOS (IHD) for the analyses.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • CanagliflozinDrug

    Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication

  • DPP4 inhibitorDrug

    DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications

  • LiraglutideDrug

    Liraglutide dispensing claim is used as the Exposure drug in LEADER replication

  • SaxagliptinDrug

    Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication

  • 2nd generation SulfonylureaDrug

    2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-point MACETime frame: Follow up begins the day after drug initiation for the three investigated studies [a median of 134-167 days]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Gothenburg, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.